JP2022524882A5 - - Google Patents
Info
- Publication number
- JP2022524882A5 JP2022524882A5 JP2021555590A JP2021555590A JP2022524882A5 JP 2022524882 A5 JP2022524882 A5 JP 2022524882A5 JP 2021555590 A JP2021555590 A JP 2021555590A JP 2021555590 A JP2021555590 A JP 2021555590A JP 2022524882 A5 JP2022524882 A5 JP 2022524882A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- lymphocytes
- il2rα
- sequence
- intermediate affinity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CUCU-2019-0021 | 2019-03-15 | ||
| CU2019000021A CU24712B1 (es) | 2019-03-15 | 2019-03-15 | Método para la expansión y diferenciación de linfocitos t y células nk en terapias de transferencia adoptiva |
| PCT/CU2020/050002 WO2020187340A2 (es) | 2019-03-15 | 2020-03-09 | Método para la expansión y diferenciación de linfocitos t y células nk en terapias de transferencia adoptiva |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022524882A JP2022524882A (ja) | 2022-05-10 |
| JP2022524882A5 true JP2022524882A5 (enExample) | 2023-01-27 |
| JP7572371B2 JP7572371B2 (ja) | 2024-10-23 |
Family
ID=72087852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021555590A Active JP7572371B2 (ja) | 2019-03-15 | 2020-03-09 | 養子移入療法（Ａｄｏｐｔｉｖｅ ｔｒａｎｓｆｅｒ ｔｈｅｒａｐｉｅｓ）におけるＴリンパ球及びＮＫ細胞の拡大増殖及び分化のための方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20220152107A1 (enExample) |
| EP (1) | EP3940063A2 (enExample) |
| JP (1) | JP7572371B2 (enExample) |
| KR (1) | KR20220012224A (enExample) |
| CN (1) | CN113785048B (enExample) |
| AR (1) | AR118369A1 (enExample) |
| AU (1) | AU2020242520B2 (enExample) |
| BR (1) | BR112021018100A2 (enExample) |
| CA (1) | CA3133736A1 (enExample) |
| CO (1) | CO2021013127A2 (enExample) |
| CU (1) | CU24712B1 (enExample) |
| EA (1) | EA202192447A1 (enExample) |
| MX (1) | MX2021011120A (enExample) |
| MY (1) | MY206651A (enExample) |
| SG (1) | SG11202109574QA (enExample) |
| TW (1) | TW202102667A (enExample) |
| WO (1) | WO2020187340A2 (enExample) |
| ZA (1) | ZA202107758B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019215034C1 (en) | 2018-02-01 | 2022-01-06 | Nkmax Co., Ltd. | Method of producing natural killer cells and composition for treating cancer |
| WO2019165121A1 (en) | 2018-02-21 | 2019-08-29 | Board Of Regents, The University Of Texas System | Methods for activation and expansion of natural killer cells and uses therof |
| US12365871B2 (en) | 2020-04-28 | 2025-07-22 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| WO2023004004A1 (en) * | 2021-07-23 | 2023-01-26 | Merck Sharp & Dohme Llc | Il-2 muteins for treating cancer or infection |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1941028A2 (en) * | 2005-08-08 | 2008-07-09 | Fondazione Centro San Raffaele Del Monte Tabor | Use of common gamma chain cytokines for the visualization, isolation and genetic modification of memory t lymphocytes. |
| US20100254958A1 (en) | 2007-10-24 | 2010-10-07 | Anne Letsch | Antigen-Specific T-Cell Preparations from Bone Marrow |
| CU23923B1 (es) | 2010-11-12 | 2013-07-31 | Ct De Inmunología Molecular | Polipéptidos derivados de la il-2 con actividad agonista |
| AU2013289971A1 (en) * | 2012-07-13 | 2015-01-22 | The Trustees Of The University Of Pennsylvania | Enhancing activity of CAR T cells by co-introducing a bispecific antibody |
| WO2017136818A2 (en) * | 2016-02-05 | 2017-08-10 | Washington University | Compositions and methods for targeted cytokine delivery |
-
2019
- 2019-03-15 CU CU2019000021A patent/CU24712B1/es unknown
-
2020
- 2020-03-09 CA CA3133736A patent/CA3133736A1/en active Pending
- 2020-03-09 BR BR112021018100A patent/BR112021018100A2/pt unknown
- 2020-03-09 US US17/439,293 patent/US20220152107A1/en active Pending
- 2020-03-09 EA EA202192447A patent/EA202192447A1/ru unknown
- 2020-03-09 AU AU2020242520A patent/AU2020242520B2/en active Active
- 2020-03-09 KR KR1020217033073A patent/KR20220012224A/ko not_active Ceased
- 2020-03-09 EP EP20757209.0A patent/EP3940063A2/en active Pending
- 2020-03-09 JP JP2021555590A patent/JP7572371B2/ja active Active
- 2020-03-09 MY MYPI2021005276A patent/MY206651A/en unknown
- 2020-03-09 WO PCT/CU2020/050002 patent/WO2020187340A2/es not_active Ceased
- 2020-03-09 SG SG11202109574Q patent/SG11202109574QA/en unknown
- 2020-03-09 MX MX2021011120A patent/MX2021011120A/es unknown
- 2020-03-09 CN CN202080020973.5A patent/CN113785048B/zh active Active
- 2020-03-12 TW TW109108199A patent/TW202102667A/zh unknown
- 2020-03-13 AR ARP200100724A patent/AR118369A1/es unknown
-
2021
- 2021-09-30 CO CONC2021/0013127A patent/CO2021013127A2/es unknown
- 2021-10-13 ZA ZA2021/07758A patent/ZA202107758B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shankar et al. | Genome engineering of induced pluripotent stem cells to manufacture natural killer cell therapies | |
| Daher et al. | CAR‐NK cells: the next wave of cellular therapy for cancer | |
| Liu et al. | NK cell-based cancer immunotherapy: from basic biology to clinical development | |
| Dagher et al. | Forks in the road for CAR T and CAR NK cell cancer therapies | |
| Shimasaki et al. | Expanded and armed natural killer cells for cancer treatment | |
| Dawson et al. | Antigen-specific regulatory T cells: are police CARs the answer? | |
| JP7584437B2 (ja) | 抗ｂｃｍａ ｃａｒ ｔ細胞の製造 | |
| AU2020242520B2 (en) | Method for the expansion and differentiation of T lymphocytes and NK cells in adoptive transfer therapies | |
| Flutter et al. | Nonhematopoietic antigen blocks memory programming of alloreactive CD8+ T cells and drives their eventual exhaustion in mouse models of bone marrow transplantation | |
| Sabry et al. | Killers at the crossroads: The use of innate immune cells in adoptive cellular therapy of cancer | |
| Liu et al. | Comparison of common γ-chain cytokines, interleukin-2, interleukin-7, and interleukin-15 for the in vitro generation of human tumor-reactive T lymphocytes for adoptive cell transfer therapy | |
| Payne et al. | Adoptive cellular therapy of cancer: exploring innate and adaptive cellular crosstalk to improve anti-tumor efficacy | |
| Karahan et al. | TCR-NK cells: a novel source for adoptive immunotherapy of cancer | |
| Bagheri et al. | Current progress in cancer immunotherapy based on natural killer cells | |
| Qian et al. | Recent advances in adoptive cell therapy for cancer immunotherapy | |
| Hu et al. | Application of adoptive cell therapy in malignant melanoma | |
| CA3161510A1 (en) | Improved process for culturing tumor-infiltrating lymphocytes for therapeutic use | |
| Petrozziello et al. | Exploiting cytokines in adoptive T-cell therapy of cancer | |
| Jiang et al. | HLA Tetramer–Based Artificial Antigen-Presenting Cells Efficiently Stimulate CTLs Specific for Malignant Glioma | |
| JP2025516264A (ja) | 多重化ｔ細胞受容体組成物、その併用療法、及び使用 | |
| Marin et al. | “Off the Shelf” CAR‐T/NK Cells | |
| Jin et al. | Approaches for generation of anti-leukemia specific T cells | |
| Birch et al. | Biology of NK cells and NK cells in clinic | |
| Cabré Margalef | Beyond CAR-T: Advancements in CAR-NK and CAR-NKT Therapies for Cancer Treatment | |
| Xiaobing et al. | Induction of cytotoxic T-lymphocytes specific for malignant glioma by HLA dimer-based artificial antigen-presenting cells |